SAN FRANCISCO HEALTH PLAN *Here for you*	**Pharmacy Services** **San Francisco Health Plan Pharmacy & Therapeutics Committee** **Wednesday, October 18, 2017** **7:30AM – 9:30AM** **50 Beale St., 13th Floor, San Francisco, CA 94119**	
Meeting called by:	James Glauber, MD	**Minutes:** Sheila Zeno, CPhT (SFHP Pharmacy Analyst) Back-up: Grace Dadios (SFHP Health Services Dept. Specialist)
Meeting Objective:	Vote on proposed formulary and prior authorization(PA) criteria changes	**Type of meeting:** Quarterly
Attendees:	**Voting Members:** James Glauber, MD (SFHP Chief Medical Officer) Ronald Ruggiero, Pharm. D Robert (Brad) Williams, MD Shawn Houghtaling, Pharm. D. Linda Truong, Pharm. D. Maria Lopez, Pharm. D Joseph Pace, MD Steven Wozniak, MD	**Others in Attendance:** Kaitlin Hawkins, Pharm. D (SFHP Pharmacist) Ralph Crowder, R.Ph. (SFHP Pharmacist) Ryan Cotten, Pharm. D (SFHP Resident Pharmacist) Jessica Shost, Pharm. D (SFHP Resident Pharmacist) Jenna Heath, Pharm. D (PerformRx Pharmacist) Lauren Megargell, Pharm. D (Perform Rx Pharmacist) Anthonia Chimezie, Pharm. D (Mission Wellness Resident Pharmacist) Scott Stepien (IPSEN Biopharma) Dawn Dynak (Gilead Sciences)
Members Absent:	Lisa Ghotbi, Pharm. D (SFHP Director of Pharmacy) Nicolas Jew, MD Ted Li, MD Jamie Ruiz, MD	
Meeting Materials:	Summary of all approved changes are posted under "Materials" section at http://www.sfhp.org/providers/formulary/pharmacy-therapeutics-committee/ SFHP formulary is located at http://www.sfhp.org/providers/formulary/sfhp-formulary/ SFHP prior authorization criteria are located at http://www.sfhp.org/files/providers/formulary/Prior_Auth_Criteria.pdf	

	Topic	Brought By	Discussion	Action
1.	Call to Order	James Glauber	The meeting was called to order at 7:30 am.	
2.	Agenda overview and other topics	James Glauber	Introduction agenda topics.	Conflicts of Interest checked and instructions given.

	Topic	Brought By	Discussion	Action
3.	Informational Updates	James Glauber Ralph Crowder	Staffing updates: We would like to welcome our new P&T committee member; Maria Lopez, Pharm. D; the president of Clinical Pharmacy Services and Residency Program Director of Mission Wellness Pharmacy in San Francisco.	
4.	Review and Approval of October 18, 2017 P&T minutes and August 29, 2017 Interim Vote minutes	James Glauber	The committee requested no corrections to the minutes.	**VOTE:** **Review and Approval of October 18, 2017 P&T Minutes** *Motion*: Ronald Ruggiero; 2nd Shawn Houghtaling *Vote:* Unanimous approval (8/8)
	******Adjourn to Closed Session****** Closed Session pursuant to Welfare and Institutions Code Section 14087.36 (w)			
5.	Discussion and Recommendation for Change to SFHP Formulary and Prior Authorization Criteria for Select Drug Classes **Pain:** o Opioid Analgesics and Combinations Class Review and DUR Proposal o Non-opioid Analgesics Abbreviated Review *(17- 42 October of 2017 P&T Packet)*	Jenna Heath Kaitlin Hawkins *Jessica Shost* *Ryan Cotten*	*The plan presented therapeutic review and recommendations for Pain medications.* *Major recommendations included the following:* *Formulary Recommendations:* (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO and Healthy San Francisco) • Add age minimum of 18 years of age to both tramadol containing products on formulary: tramadol (Ultram®) 50 mg tablet and tramadol/acetaminophen (Ultracet®) 37.5-325 mg tablet • Remove hydromorphone liquid and suppository from formulary and remove prior authorization due to no utilization, no requests, and no criteria • List the following as T5 non-formulary based on Medi-Cal covered drugs list: o hydrocodone/acetaminophen oral solution o levorphanol oral tablet o oxymorphone 1 mg/ml ampule *PA Criteria Recommendations:* Update short-acting criteria to reflect formulary status and include criteria for non-formulary hydrocodone/acetaminophen combinations *Drug Utilization Review Recommendations:* Develop an "Initial Opioid Days-Supply' edit to restrict initial opioid fills to seven (7) days for short-acting opioids only: o Initial opioids: no opioid paid claim in the past 180 days o Exemptions: paid oncology medication	**VOTE:** **Pain:** Approve recommendations as presented. ***Opioid Analgesics and Combinations Class Review*** *Motion*: Shawn Houghtaling; 2nd Steven Wozniak *Vote:* Unanimous approval (8/8) ***DUR Proposal*** *Motion*: Robert (Brad) Williams; 2nd Steven Wozniak *Vote:* Unanimous approval (8/8) ***Non-opioid Analgesics Abbreviated Review*** *Motion*: Ronald Ruggiero; 2nd Joseph Pace *Vote:* Unanimous approval (8/8)

	Topic	Brought By	Discussion	Action
			claim in the last 180 days, NPI list for approved providers Committee Discussion: *The committee questioned the effectiveness of this edit. The discussion lead to expressing the need to address this issue with all physicians and these edits will act as reminders to assist with prescribing practices.*	
6.	**Neurology** • Migraine Class Review • Movement Disorders Class Review (P43 - 73 of October 2017 P&T Packet)		*The plan presented therapeutic review and recommendations for Neurology medications. Major recommendations included the following:* *Formulary Recommendations:* (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO, and Healthy San Francisco) • Remove age limit from rizatriptan oral tablets based on FDA-approved indication • Change butalbital/acetaminophen/caffeine 50-325-40mg tablets formulary status from T1-F to T3-F/PA due to limited utilization, safety concerns, and more efficacious first-line therapies • Change butalbital/acetaminophen/caffeine 50-325-40mg capsules formulary status from T3-F/PA to NF-NL due to no utilization, safety concerns, and more efficacious first-line therapies • Add Ingrezza™ and Austedo® to formulary T4 with PA required *PA Criteria Recommendations:* • Update Anti-Migraine Preparations and Triptans criteria to reflect formulary status changes. • New criteria proposed requiring diagnosis, baseline evaluation of symptoms using Abnormal Involuntary Movement Scale (AIMS) or Extrapyramidal Symptom Rating Scale (ESRS), and prior drug therapy. Recommend combining criteria for Ingrezza™ and Austedo® with tetrabenazine criteria. Recommend including required baseline Total Maximal Chorea (TMC) or Total Functioning Capacity (TFC) and removing requirements from package insert asking for physician attestation only. Committee Discussion: *The committee had no comments or questions.*	**VOTE:** **Neurology:** ***Migraine Class Review*** Approve recommendations as presented with the noted addition of increasing the quantity limit of all formulary migraines to match. *Motion:* Robert (Brad) Williams; 2nd Shawn Houghtaling *Vote:* Unanimous approval (8/8) ***Movement Disorders Class Review*** Approve recommendations as presented. *Motion:* : Shawn Houghtaling; 2nd Steven Wozniak *Vote:* Unanimous approval (8/8)

	Topic	Brought By	Discussion	Action
7.	**Rheumatology** • Biologic and Non-Biologic DMARDs Class Review • Gout (P74 -120 of October 2017 P&T Packet)		*The plan presented therapeutic review and recommendations for Rheumatology.* *Major recommendations included the following:* *Formulary Recommendations:* (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO, and Healthy San Francisco): Remove quantity limits from formulary non-biologics DMARDs • Add minocycline 75 mg capsule to formulary T1 with quantity limit to align with other strengths, based on competitive pricing *PA Criteria Recommendations:* • Update criteria to include additional non-formulary medications and to indicate "non-preferred medications" and "preferred medications". • Update criteria to include requirements for Zurampic® Committee Discussion: ***Follow-up**: Pricing for combo product colchicine/probenecid.*	**VOTE:** **Rheumatology** ***Biologic and Non-Biologic DMARDs Class Review*** Approve recommendations as presented. *Motion:* Shawn Houghtaling; 2nd Joseph Pace *Vote:* Unanimous approval (8/8) ***Gout*** Approve recommendations as presented. *Motion:* Shawn Houghtaling; 2nd Joseph Pace *Vote:* Unanimous approval (8/8)
8.	**Infectious Disease** • Hepatitis C Virus Class Review (P121-143 of October 2017 P&T Packet)		*The plan presented therapeutic review and recommendations for Infectious Disease medications. Major recommendations are listed below.* Formulary Recommendations: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO, and Healthy San Francisco): • Remove Daklinza, Sovaldi, Technivie, and Viekira Pak from formulary due to low projected utilization PA Criteria Recommendations: • Update criteria to include preferred regimens for renal impairment, unique populations, and update treatment experienced criteria based on prior regimen Committee Discussion: *The committee had no comments or questions.*	**VOTE:** **Infectious Disease** ***Hepatitis C Virus Class Review*** Approve recommendations as presented. *Motion:* Ronald Ruggiero; 2nd Shawn Houghtaling *Vote:* Unanimous approval (8/8)

	Topic	Brought By	Discussion	Action
9.	**Genitourinary** • Benign Prostatic Hypertension Class Review • Genitourinary Miscellaneous Abbreviated Review (P144-160 of October 2017 P&T Packet)		*The plan presented therapeutic review and recommendations for Genitourinary medications. Major recommendations are listed below.* Formulary Recommendations: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO, and Healthy San Francisco): • Remove quantity limits from tamsulosin, finasteride, and afluzosin. • Add potassium citrate/citric acid packet to formulary with quantity limit #120 packets per 30 days due to competitive pricing • Tier fesoterodine ER and Vesicare® as T5 (non-formulary) based on California Department of Health Care Services (DHCS) Covered Drug List • Remove Gelnique® 3% gel from PA criteria (currently non-formulary) due to drug discontinuation PA Criteria Recommendations: • Update criteria for Genitourinary Antispasmodics and Anti-Cholinergics with editorial changes. Committee Discussion: *The committee had no comments or questions.*	**VOTE:** **Genitourinary** ***Benign Prostatic Hypertension Class Review*** Approve recommendations as presented. *Motion:* Robert (Brad) Williams; 2nd Shawn Houghtaling *Vote:* Unanimous approval (8/8) ***Genitourinary Miscellaneous Abbreviated Review*** Approve recommendations as presented. *Motion:* Maria Lopez; 2nd Ronald Ruggiero *Vote:* Unanimous approval (8/8)
10.	**Cardiology** • Anticoagulants Class Review • Antiplatelets Class Review (P161-193 of October 2017 P&T Packet)		*The plan presented therapeutic review and recommendations for Cardiology medications. Major recommendations are listed below.* Formulary Recommendations: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO, and Healthy San Francisco): • No changes recommended. PA Criteria Recommendations: • Update criteria to reflect new dosage for Pradaxa®. Committee Discussion: *The committee had no comments or questions.*	**VOTE:** **Cardiology** ***Anticoagulants Class Review*** Approve recommendations as presented. *Motion:* Robert (Brad) Williams; 2nd Ronald Ruggiero *Vote:* Unanimous approval (8/8) ***Antiplatelets Class Review*** Approve recommendations as presented. *Motion:* Shawn Houghtaling; 2nd Joseph Pace *Vote:* Unanimous approval (8/8)

	Topic	Brought By	Discussion	Action
11.	**Pulmonology** • Idiopathic Pulmonary Fibrosis Class Review (P194-202 of October 2017 P&T Packet)		*The plan presented therapeutic review and recommendations for Pulmonology medications. Major recommendations are listed below.* Formulary Recommendations: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO, and Healthy San Francisco): • Add Esbriet® to formulary T4 with PA required • Keep Ofev® as non-formulary PA Criteria Recommendations: • New criteria proposed requiring diagnosis, baseline evaluation of pulmonary function by FVC, and prior drug therapy. Committee Discussion: *The committee had no comments or questions.*	**VOTE:** **Pulmonology** ***Idiopathic Pulmonary Fibrosis Class Review*** Approve recommendations as presented. *Motion:* Robert (Brad) Williams; 2nd Joseph Pace *Vote:* Unanimous approval (8/8)
12.	**Dermatology** • Dupixent Monograph (P203- 211 of October 2017 P&T Packet)		*The plan presented therapeutic review and recommendations for Dermatology medications. Major recommendations are listed below.* Formulary Recommendations: (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO, and Healthy San Francisco): • Maintain Dupixent® as non-formulary. PA Criteria Recommendations: • Combine Dupixent® criteria with current Eucrisa® and Topical Calcineurin Inhibitor criteria to allow for stepwise treatment approach for atopic dermatitis. Committee Discussion: *The committee had no comments or questions.*	**VOTE:** **Dermatology** ***Benign Prostatic Hypertension Class Review*** Approve recommendations as presented. *Motion:* Shawn Houghtaling; 2nd Joseph Pace *Vote:* Unanimous approval (8/8)
	******RECONVENE IN OPEN SESSION******			
13.	**Summary of Closed Session**	James Glauber	Reconvened Open session around 9:15am	*Non-voting*
14.	**New Prior Authorization Blanket Criteria – Compounded Drugs** (P212 October 2017 P&T Packet)	Ralph Crowder	*The plan presented new prior authorization (PA) blanket criteria for compounded drug request: Major areas to note:* • *Non-Formulary/Prior Authorization required* • **Coverage Duration:** Initial: Not to exceed 3 months Reauthorization: 6 months • Diagnosis appropriate for medications contained in the compounded product. • Approval Quantity Limit* 30 day supply *For detail of changes, please see page 212 of the P&T packet.* Committee Discussion: *There was a question regarding compounding testosterone. Because no bulk medications can be used in a covered compounded product, it will*	***VOTE:*** ***New Prior Authorization Blanket Criteria – Compounded Drugs*** *Approve recommendations as presented.* *Motion: Ronald Ruggiero; 2nd Robert (Brad) Williams* *Vote: Unanimous approval (8/8)*

	Topic	Brought By	Discussion	Action
			not be covered.	
16.	**Pharmacy Policy & Procedure Updates and Monitoring** (P213-229 October 2017 P&T Packet)	Ralph Crowder	*The plan presented changes to the Pharmacy Policy and Procedures (P&P):* *Pharm 03- Pharmacy Network Credentialing* *Pharm 09- Pharmaceutical Patient Safety* *Pharm 10- Pharmacy Residency Program* *Pharm 11- Member Reimbursement for Pharmacy Services* For detail of changes, please see pages 213-229 of P&T packet. Committee Discussion: *The committee had no comments or questions*	**VOTE:** **Pharmacy Policy and Procedure Updates** Approve recommendations as presented. *Motion:* Maria Lopez; 2nd Linda Truong *Vote:* Unanimous approval (8/8)
17.	**Review and Approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market** (P230-239 of October 2017 P&T Packet)	Kaitlin Hawkins	*The plan presented interim formulary changes and formulary status for new drugs to market*. Committee Discussion: *The committee had no comments or questions*	**VOTE:** **Review and Approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market** Approve recommendations as presented. *Motion:* Linda Truong; 2nd Shawn Houghtaling *Vote:* Unanimous approval (8/8)
18.	**Follow-up items from prior P&T meetings** (P240-241 of October 2017 P&T Packet)	Kaitlin Hawkins	*The plan presented Follow-up items from prior P&T meetings:* *Lidoderm utilization- added to formulary May 2016* • The total monthly spending, claim volume and number of utilizing members have increased per month following its addition to the formulary at P&T in April 2016 (enacted in May 2016). *Epipen utilization- formulary change May 2017* • The formulary product was changed from EpiPen® and EpiPen Jr® to corresponding generic formulations, and a quantity limit of three two-autoinjector pen packs per year was enacted. While the cost per member per month (PMPM) increased from 2015 to 2016, PMPM cost in this class has decreased slightly from 2016 to 2017. Committee Discussion: *The committee had no comments or questions*	*Non-voting item*
19.	**Informational Update on New Developments in the Pharmacy Market**	Jenna Heath	*The plan provided information on new developments in the pharmacy market.* For detail of changes, please see pages 242-250 of P&T packet.	*Non-voting item*

	Topic	Brought By	Discussion	Action
	(P242-250 of July 2017 P&T Packet)			
20.	**Adjournment**	James Glauber	The meeting adjourned at 9:27 am. 2017-18 P&T Committee Meeting dates are: • Wednesday, January 17, 2018 • Wednesday, April 18, 2018 • Wednesday, July 18, 2018 • Wednesday, October 17, 2018	

The meeting was adjourned at 9:27 AM

Respectfully submitted by:

November 21, 2017

James Glauber, MD, MPH
Chief Medical Officer

Date